Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1990 Mar 3;300(6724):553–555. doi: 10.1136/bmj.300.6724.553

Raynaud's syndrome.

E D Cooke 1, A N Nicolaides 1
PMCID: PMC1662376  PMID: 1691027

Full text

PDF
553

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldoori M., Campbell W. B., Dieppe P. A. Nifedipine in the treatment of Raynaud's syndrome. Cardiovasc Res. 1986 Jun;20(6):466–470. doi: 10.1093/cvr/20.6.466. [DOI] [PubMed] [Google Scholar]
  2. Belch J. J., Madhok R., Shaw B., Leiberman P., Sturrock R. D., Forbes C. D. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon. Lancet. 1985 May 25;1(8439):1180–1183. doi: 10.1016/s0140-6736(85)92862-4. [DOI] [PubMed] [Google Scholar]
  3. Belch J. J., Newman P., Drury J. K., McKenzie F., Capell H., Leiberman P., Forbes C. D., Prentice C. R. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet. 1983 Feb 12;1(8320):313–315. doi: 10.1016/s0140-6736(83)91624-0. [DOI] [PubMed] [Google Scholar]
  4. Birmingham A. T., Szolcsányi J. Competitive blockade of adrenergic alpha-receptors and histamine receptors by thymoxamine. J Pharm Pharmacol. 1965 Jul;17(7):449–458. doi: 10.1111/j.2042-7158.1965.tb07701.x. [DOI] [PubMed] [Google Scholar]
  5. Black C. M. Scleroderma. Br J Hosp Med. 1979 Jul;22(1):28, 30, 32-3 passim. [PubMed] [Google Scholar]
  6. Browse N. L., Gray L., Jarrett P. E., Morland M. Blood and vein-wall fibrinolytic activity in health and vascular disease. Br Med J. 1977 Feb 19;1(6059):478–481. doi: 10.1136/bmj.1.6059.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cooke E. D., Bowcock S. A., Watkins C. J., Rustin M. H., Kirby J. D. CL115,347, an analogue of prostaglandin E2. Peripheral circulatory effects of single ascending doses administered transdermally in normal subjects and in patients with Raynaud's phenomenon. Angiology. 1985 Dec;36(12):867–871. doi: 10.1177/000331978503601205. [DOI] [PubMed] [Google Scholar]
  8. Cunliffe W. J., Menon I. S. Blood fibrinolytic activity in diseases of small blood vessels and the effect of low molecular weight dextran. Br J Dermatol. 1969 Mar;81(3):220–225. doi: 10.1111/j.1365-2133.1969.tb16012.x. [DOI] [PubMed] [Google Scholar]
  9. DiGiacomo R. A., Kremer J. M., Shah D. M. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158–164. doi: 10.1016/0002-9343(89)90261-1. [DOI] [PubMed] [Google Scholar]
  10. Fischer S., Weber P. C. Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature. 1984 Jan 12;307(5947):165–168. doi: 10.1038/307165a0. [DOI] [PubMed] [Google Scholar]
  11. Fischer S., Weber P. C. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun. 1983 Nov 15;116(3):1091–1099. doi: 10.1016/s0006-291x(83)80254-x. [DOI] [PubMed] [Google Scholar]
  12. Freedman R. R., Ianni P. Role of cold and emotional stress in Raynaud's disease and scleroderma. Br Med J (Clin Res Ed) 1983 Nov 19;287(6404):1499–1502. doi: 10.1136/bmj.287.6404.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goodfield M. J., Rowell N. R. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis. Br J Dermatol. 1988 Nov;119(5):643–646. doi: 10.1111/j.1365-2133.1988.tb03477.x. [DOI] [PubMed] [Google Scholar]
  14. Goyle K. B., Dormandy J. A. Abnormal blood viscosity in Raynaud's phenomenon. Lancet. 1976 Jun 19;1(7973):1317–1318. doi: 10.1016/s0140-6736(76)92651-9. [DOI] [PubMed] [Google Scholar]
  15. Grigg M. J., Nicolaides A. N., Papadakis K., Wolfe J. H. The efficacy of thymoxamine in primary Raynaud's phenomenon. Eur J Vasc Surg. 1989 Aug;3(4):309–313. doi: 10.1016/s0950-821x(89)80066-0. [DOI] [PubMed] [Google Scholar]
  16. Jarrett P. E., Morland M., Browse N. L. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J. 1978 Aug 19;2(6136):523–525. doi: 10.1136/bmj.2.6136.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jobe J. B., Beetham W. P., Jr, Roberts D. E., Silver G. R., Larsen R. F., Hamlet M. P., Sampson J. B. Induced vasodilation as a home treatment for Raynaud's disease. J Rheumatol. 1985 Oct;12(5):953–956. [PubMed] [Google Scholar]
  18. Jobe J. B., Sampson J. B., Roberts D. E., Beetham W. P., Jr Induced vasodilation as treatment for Raynaud's disease. Ann Intern Med. 1982 Nov;97(5):706–709. doi: 10.7326/0003-4819-97-5-706. [DOI] [PubMed] [Google Scholar]
  19. Kahaleh M. B., Osborn I., Leroy E. C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982 May;96(5):610–613. doi: 10.7326/0003-4819-96-5-610. [DOI] [PubMed] [Google Scholar]
  20. Keenan E. J., Porter J. M. Alpha-adrenergic receptors in platelets from patients with Raynaud's syndrome. Surgery. 1983 Aug;94(2):204–209. [PubMed] [Google Scholar]
  21. Martin M. F., Dowd P. M., Ring E. F., Cooke E. D., Dieppe P. A., Kirby J. D. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis. 1981 Aug;40(4):350–354. doi: 10.1136/ard.40.4.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McGrath M. A., Peek R., Penny R. Blood hyperviscosity with reduced skin blood flow in scleroderma. Ann Rheum Dis. 1977 Dec;36(6):569–574. doi: 10.1136/ard.36.6.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McHugh N. J., Csuka M., Watson H., Belcher G., Amadi A., Ring E. F., Black C. M., Maddison P. J. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis. 1988 Jan;47(1):43–47. doi: 10.1136/ard.47.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Meyrick Thomas R. H., Rademaker M., Grimes S. M., MacKay A., Kovacs I. B., Cook E. D., Bowcock S. M., Kirby J. D. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol. 1987 Aug;117(2):237–241. doi: 10.1111/j.1365-2133.1987.tb04122.x. [DOI] [PubMed] [Google Scholar]
  25. Myers K. A., Hobbs J. T., Irvine W. T. Haemodynamic action of thymoxamine (an alpha-adrenergic blocking agent) in occlusive peripheral arterial disease. Cardiovasc Res. 1968 Oct;2(4):360–366. doi: 10.1093/cvr/2.4.360. [DOI] [PubMed] [Google Scholar]
  26. Nahir A. M., Schapira D., Scharf Y. Double-blind randomized trial of nitroderm TTS in the treatment of Raynaud's phenomenon. Isr J Med Sci. 1986 Feb;22(2):139–142. [PubMed] [Google Scholar]
  27. Rademaker M., Cooke E. D., Almond N. E., Beacham J. A., Smith R. E., Mant T. G., Kirby J. D. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ. 1989 Mar 4;298(6673):561–564. doi: 10.1136/bmj.298.6673.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rademaker M., Thomas R. H., Provost G., Beacham J. A., Cooke E. D., Kirby J. D. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J. 1987 Aug;63(742):617–620. doi: 10.1136/pgmj.63.742.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rice R. Fish oils--their significance to human health. J R Soc Med. 1988 Sep;81(9):499–501. doi: 10.1177/014107688808100902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Roald O. K., Seem E. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J (Clin Res Ed) 1984 Sep 8;289(6445):577–579. doi: 10.1136/bmj.289.6445.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rustin M. H., Almond N. E., Beacham J. A., Brooks R. J., Jones D. P., Cooke E. D., Dowd P. M. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol. 1987 Dec;117(6):751–758. doi: 10.1111/j.1365-2133.1987.tb07356.x. [DOI] [PubMed] [Google Scholar]
  32. Seibold J. R., Terregino C. A. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon. J Rheumatol. 1986 Apr;13(2):337–340. [PubMed] [Google Scholar]
  33. Singer H. A., Peach M. J. Endothelium-dependent relaxation of rabbit aorta. I. Relaxation stimulated by arachidonic acid. J Pharmacol Exp Ther. 1983 Sep;226(3):790–795. [PubMed] [Google Scholar]
  34. Sorkin E. M., Clissold S. P., Brogden R. N. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 1985 Sep;30(3):182–274. doi: 10.2165/00003495-198530030-00002. [DOI] [PubMed] [Google Scholar]
  35. Tan E. M., Chan E. K., Sullivan K. F., Rubin R. L. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988 May;47(2):121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  36. Terregino C. A., Seibold J. R. Influence of the menstrual cycle on Raynaud's phenomenon and on cold tolerance in normal women. Angiology. 1985 Feb;36(2):88–95. doi: 10.1177/000331978503600204. [DOI] [PubMed] [Google Scholar]
  37. Yardumian D. A., Isenberg D. A., Rustin M., Belcher G., Snaith M. L., Dowd P. M., Machin S. J. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol. 1988 Jun;27(3):220–226. doi: 10.1093/rheumatology/27.3.220. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES